Connect with us

Cannabis News

Tilray Medical announces commercial launch of medical cannabis in Panama

Published

on

Tilray Medical has announced the launch of its first medical cannabis product in Panama, part of the company’s continued global expansion and commitment to improving patient access to pharmaceutical grade cannabinoids worldwide.

Following the successful shipment of Tilray Oral Solution CBD100 from Tilray Medical’s EU-GMP certified production facilities in Portugal through a joint venture with Solana Life Group S. de RL, the Product is to be distributed through Farmacias Arrocha, one of the leading pharmaceutical chains in Panama, where patients will be able to access Tilray Oral Solution CBD with medical prescription100. This is expected to provide patients and healthcare professionals with access to regulated medical cannabis of pharmaceutical quality through established healthcare channels.

Rajnish Ohri, International President, Tilray Brands, said: “At Tilray Medical, we believe that every patient deserves access to safe, consistent, pharmaceutical-grade cannabis products. The launch in Panama reflects our broader vision to expand access to cannabinoid-based medicines around the world. We want pharmacists and patients to help shape the future of responsible access, advance medical education and provide high-quality treatment options that improve lives.”

The launch supports the Panamanian medical cannabis framework established by Law 242 of 2021 and follows important regulatory advances made by the Ministry of Health, including No. 0406 of May 12, 2026. The decision, which established the main conditions for the admission of patients. The Ministry also recently introduced the System for the Identification of Medical Cannabis Users and Authorized Caregivers (SIUCMAA), creating a structured way to authorize medical practitioners and register patients.

Manufactured in Portugal under strict European Union Good Manufacturing Practice (EU-GMP) standards, Tilray Oral Solution CBD100 is intended for use in patients with qualified medical conditions permitted under Panamanian law, where permitted. The products reflect Tilray Medical’s longstanding commitment to pharmaceutical quality, product consistency, patient safety and regulatory compliance.

Tilray Medical’s advanced cultivation and manufacturing facilities in Portugal serve as a strategic global export hub, supplying EU-GMP certified medical cannabis products to regulated markets worldwide. The platform enables Tilray Medical to effectively support growing international demand while maintaining the highest pharmaceutical manufacturing standards across its global operations.

For more information:
Tilray
www.tilray.com

Cannabis News

Medical Marijuana Is ‘Effective’ In Providing Relief To Patients With Restless Legs Syndrome, Study Shows

Published

on

By

People with restless leg syndrome (RLS) may find “significant” long-term relief with cannabis treatment, according to a new study.

While dopamine agonists have traditionally been the “first-line treatment” for RLS, recent studies indicate that gabapentinoids are now being recommended, the researchers said. Because cannabinoids, like gabapentinoids, inhibit a certain type of amino acid associated with the disorder, scientists decided to test their therapeutic effectiveness.

The open-label exploratory study, conducted by European researchers at the University of Madrid and published in the Journal of Neurology, found that a cannabis product containing 2.7 mg of THC and 2.5 mg of CBD was “effective in reducing RLS severity” among patients with multiple sclerosis and “associated idiopathic RLS.”

“Improvements were observed after 1 to 3 months of treatment and were maintained after 1 year among patients who continued therapy,” the study of 18 patients with RLS showed. For those who remained in treatment after a year, 67 percent “continued to show sustained improvement.”

The the findings it may not be surprising that cannabis in particular is known to reduce the severity of muscle spasms and related conditions, but its effectiveness for RLS is remarkable given that no state specifically lists it as a condition for medical cannabis.

Of course, RLS can be a symptom of other general disorders like multiple sclerosis, and some states give doctors more latitude to make recommendations for medical marijuana for any condition they see fit.

In any case, research outside of Spain could be based on research into alternative treatment options that could replace dopamine agonists in the treatment of restless legs syndrome.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Wyoming AG keeps cannabis on Schedule I, rejects federal reclassification

Published

on

By











Wyoming Attorney General Keith Kautz announced on July 7 that he would keep all marijuana products in Schedule I of Wyoming’s Controlled Substances Act, refusing to align the state’s cannabis policy with the federal reorganization order issued earlier this year.

Kautz, who also serves as Wyoming’s drug and substance abuse commissioner, held a public hearing on June 18 after filing an objection to aligning the state’s cannabis schedule with a federal amendment on May 27. State law requires the commissioner to give interested parties an opportunity to be heard after that objection, but only nine people responded. Four email comments supported leaving cannabis as a Schedule I drug, four as Schedule III. It was approved for use and one person attended the hearing to request that cannabis remain in Schedule I.

His decision follows an April 2026 order signed by U.S. Attorney General Todd Blanche that bans state-licensed medical cannabis, FDA-approved cannabis products, cannabis extracts and naturally derived delta-9 THC III.

Kautz’s office says: “After consideration of all stakeholder comments, the commissioner has determined that all marijuana products, including marijuana subject to the state’s medical marijuana license, will remain in Schedule I of the Wyoming Controlled Substances Act.”

His announcement adds, “The decision to reschedule medical marijuana and marijuana products is an important policy decision that is best left to the Wyoming Legislature and should not be made through administrative rule.”

Wyoming remains one of eight states without a medical cannabis program. A December 2020 poll by the University of Wyoming’s Wyoming Center for Polling and Analysis found that 85 percent of state residents support legalizing medical cannabis, despite a failed 2024 ballot initiative effort. Possession of three ounces or less carries up to 12 months in prison under current state law, and selling any amount is punishable by up to 10 years in prison and a $10,000 fine.

Kautz says his office will “properly schedule products approved by the United States Food and Drug Administration once that agency has approved the product,” pointing to the Schedules II and III listings of Cesamet and Dronabinol as evidence that the state complies with federal cannabinoid drug law.










Continue Reading

Cannabis News

Massachusetts Initiative To Roll Back Marijuana Legalization Officially Qualifies For November Ballot

Published

on

By

Officials in Massachusetts have formally certified an An initiative to roll back that state’s marijuana legalization law will appear on the November ballot.

The Commonwealth Secretariat’s Division of Elections notified organizers on Thursday that they had delivered enough valid signatures in the second round of petitions to put the measure before the voters—but just barely.

Under state law, Massachusetts ballot campaigns must submit signatures in two rounds. After the first presentation, the legislature has the opportunity to propose ballot measures after the organizers have presented the initial round of requests. Legislators in May he refused to act on the anti-marijuana measurehowever, and therefore the organizers had to present 12,429 more certified signatures by July 1 for the November vote.

“I am pleased to inform you that this Office has accepted 12,551 certified signatures received on or before July 1, 2026,” Michelle K. Tassinar of the Division of Elections wrote in a letter to one of the initial signatories. “The remaining signatures were voided for not being certified, inconsistent with the interpretation of (state law) or exceeding the number allowed for each county.”

“Therefore, the petition for the initiative will be printed on the November 3, 2026 state election ballot as required by the Constitution,” he said.

Meanwhile, a coalition of Massachusetts marijuana entrepreneurs, health care professionals and other advocates has launched a campaign to defeat the measure, which if enacted, would repeal laws that allow for the regulated commercial sale of recreational cannabis and home cultivation, while maintaining legal ownership and continuing the medical marijuana system.

In June, the campaign behind the legalization measure, the Coalition for a Healthy Massachusetts, released a signature-gatherer that it says showed “totally unacceptable” behavior in a recent video.

As Marihuana Moment reported, a The man was petitioning for the Massachusetts initiative, as well as a similar anti-cannabis proposal in Maine Recent social media posts suggested that voters who support legal access to marijuana should sign petitions to advance or support the reform.

The campaign later said it has “zero tolerance” for circulation tactics that would mislead petition signers.

“The identified canvasser was terminated immediately, in coordination with our vendor, upon learning of the alleged conduct,” the team said. “The behavior shown in the video would be completely unacceptable and does not reflect how this campaign works. We demand honesty, transparency and professionalism from everyone associated with our efforts.”

A video posted on Reddit shows the petitioner collecting signatures outside a Massachusetts retail store next to a sign that says “keep cannabis legal.”

When the petitioner confronted a marijuana reform supporter who recorded interactions with voters, it appears he was trying to convince them that getting the anti-cannabis measure on the ballot is important to defeating it later.

“This is what we’re fighting here. That’s why we’re voting no,” he said. “If we can bring this to a vote right here, we will vote no.”

The person who received the video noted that Massachusetts voters already approved the legalization of marijuana years ago, and the only way to immediately reverse it would be if the new ballot measure qualified for the November election. If the initiative doesn’t get enough signatures to go before the voters, state laws will remain the same.

“It’s my job,” insisted the applicant, however. “I know what I’m talking about.”

“It’s a group of wealthy out-of-state people who basically want to take marijuana back to the time when medical marijuana was the ticket,” he said. “We don’t want that to happen.”

The same man also appeared to be collecting extraordinary signatures A Maine measure that would repeal laws allowing the regulated sale of marijuana to adults and home cultivation rights for adults while maintaining legal ownership and adding new testing requirements for medical cannabis.

An employee of the prohibitionist organization Smart Approaches to Marijuana (SAM), of which the group is a member. SAM Action is largely funding anti-cannabis vote campaigns in both states, declined to comment on the petitioner’s conduct when reached by Marihuana Moment.

Campaigns have been accused of deceptive solicitation tactics before.

In Massachusetts, some voters reported the campaign used fake letters for other ballot measures on unrelated issues such as affordable housing and same-day voter registration. Supporters of legal cannabis filed a formal complaint about the tactics of the prohibitionist effortbut The State Voting Law Commission rejected the rebuttal.

The The measure faced a legal challenge from cannabis industry players he argued that it contains “irrelevant issues” and that the state attorney general’s official brief is “misleading and deficient.” State Supreme Court heard oral arguments on the case challenging the anti-marijuana initiative but after all he decided against the challenge.

Read state officials the letter Regarding the certification of the anti-marijuana ballot initiative:

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media